GF Fund Management’s LENZ Therapeutics LENZ Stock Holding History

GF Fund Management’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.78K	Sell	665 -23	-3%	-$185	﹤0.01%	580
2026 Q1	$6.29K	Buy	688 +81	+13%	+$1.14K	﹤0.01%	592
2025 Q4	$9.71K	Sell	607 -7	-1%	-$204	﹤0.01%	577
2025 Q3	$28.6K	Sell	614 -90	-13%	-$3.31K	﹤0.01%	446
2025 Q2	$20.6K	Hold	704	–	–	﹤0.01%	499
2025 Q1	$18.1K	Buy	704 +127	+22%	+$3.13K	﹤0.01%	512
2024 Q4	$16.7K	Buy	+577	New	+$17.6K	﹤0.01%	488

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

7IH

72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

GF Fund Management's LENZ Position: Q2 2026 in Review

GF Fund Management reduced its LENZ Therapeutics (LENZ) stake by 3.3% in Q2 2026, selling an estimated $185 and leaving 665 shares worth $3.78K. The position accounts for ﹤0.01% of the portfolio, ranked #580.

GF Fund Management first reported a position in LENZ in Q4 2024 and has held it in 7 quarters since. The position peaked at $28.6K in Q3 2025. 144 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

GF Fund Management held 665 shares of LENZ Therapeutics worth $3.78K as of Q2 2026.
GF Fund Management sold 23 LENZ Therapeutics shares in Q2 2026, an estimated $185.
LENZ Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #580 holding.
GF Fund Management first reported a position in LENZ Therapeutics in Q4 2024 and has held it in 7 quarters since.
GF Fund Management's LENZ Therapeutics position peaked at $28.6K in Q3 2025.
144 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.